⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28845248 | 0.62 | — | — | |
| SCHEMBL12542798 | 0.61 | — | — | |
| SCHEMBL7162800 | 0.61 | — | — | |
| SCHEMBL32667916 | 0.60 | — | — | |
| SCHEMBL31590136 | 0.57 | — | — | |
| SCHEMBL7878169 | 0.56 | — | — | |
| SCHEMBL208333 | 0.54 | — | — | |
| SCHEMBL902266 | 0.53 | — | — | |
| SCHEMBL18792570 | 0.52 | — | — | |
| SCHEMBL29496072 | 0.52 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12005127-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-11 | — | — | US | claimed |
| EP-3740480-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2024-03-06 | — | — | EP | claimed |
| US-11813267-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-14 | — | — | US | claimed |
| EP-3985003-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2023-08-09 | — | — | EP | claimed |
| EP-3985003-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2022-04-20 | — | — | EP | claimed |
| US-20210236505-A1 | SUBSTITUTED QUINOXALINE DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-08-05 | — | — | US | claimed |
| US-20210069203-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-03-11 | — | — | US | claimed |
| EP-3740480-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2020-11-25 | — | — | EP | claimed |
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | claimed |
| CN-111757876-A | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-10-09 | — | — | CN | claimed |
| US-20180161336-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | US | claimed |
| US-9987284-B2 | Substituted benzooxadiazole DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-05 | — | — | US | claimed |
| US-20160354381-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-08 | — | — | US | claimed |
| US-20160340341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-24 | — | — | US | claimed |
| US-9359380-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-07 | — | — | US | claimed |
| US-9340557-B2 | Substituted quinoxaline DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | claimed |
| EP-2970218-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014159690-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140275024-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | claimed |
| US-20140275059-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | claimed |